BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.

doi:10.1007/s00280-021-04234-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.

Cancer chemotherapy and pharmacology - 1 Mar 2021

Butt Sabeeh-Ur-Rehman, Mejias Alberto, Morelli Cristina, Torga Gonzalo, Happe Marlene, Patrikidou Anna, Arkenau Hendrik-Tobias

Abstract excerpt

The management of cancer has been traditionally dependent on the primary tumour type and specific histologic subtypes. Recently, the introduction of molecular profiling tools and its increasing use in clinical practice has facilitated the emergence of novel genomically driven treatment options within the standard of care landscape as well as in the clinical trial setting. One such aberration is mutation in v-Raf...

Topics

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Male
Middle Aged
Mitogen-Activated Protein Kinase Kinases
Mutation
Neoplasms
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 33537843
DOI: 10.1007/s00280-021-04234-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics